Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rezolute, Inc.

8.00
+0.62008.40%
Post-market: 8.000.00000.00%19:52 EDT
Volume:1.56M
Turnover:12.14M
Market Cap:695.97M
PE:-7.18
High:8.06
Open:7.43
Low:7.34
Close:7.38
52wk High:8.06
52wk Low:2.22
Shares:87.00M
Float Shares:78.03M
Volume Ratio:1.73
T/O Rate:2.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1148
EPS(LYR):-1.3302
ROE:-95.15%
ROA:-52.85%
PB:8.43
PE(LYR):-6.01

Loading ...

Company Profile

Company Name:
Rezolute, Inc.
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
68
Office Location:
275 Shoreline Drive,Suite 500,Redwood City,California,United States
Zip Code:
94065
Fax:
- -
Introduction:
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Directors

Name
Position
Nevan C. Elam
Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board
Erik Harris
Independent Director
Gil Labrucherie
Director
Nerissa C. Kreher
Director
Philippe Fauchet
Director
Wladimir Hogenhuis
Director
Young Jin Kim
Director

Shareholders

Name
Position
Nevan C. Elam
Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board
Daron Evans
Chief Financial Officer
Brian Roberts
Chief Medical Officer
Sunil Karnawat
Chief Commercial Officer